Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?

Hanquet, Germaine; Perrocheau, A; Kissling, Esther; Bruhl, Daniel Levy; Tarragó, David; Stuart, James M.; Stefanoff, Paweł; Heuberger, Sigrid; Kriz, Paula; Vergison, Anne; Greeff, Sabine C. de; Amato‐Gauci, Andrew J.; Celentano, Lucia Pastore; Disease, Ecdc Country Experts for Pneumococcal

doi:10.1016/j.vaccine.2010.03.069

Cited by 26 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In European countries, reported IPD rates in young children may thus be skewed toward more severe manifestations of IPD, such as meningitis, and may under-report mild disease [74,75]. Other differences in clinical practice (such as antimicrobial prescription guidelines), or heterogeneity in reporting requirements or case identification within the individual countries' surveillance systems may also impact reported IPD rates [34,75,77].…”

Section: Discussionmentioning

confidence: 99%

“…Finally, population characteristics such as age distribution, frequency of underlying IPD risk factors and comorbidities, and social mixing patterns may change over time. All of these factors may influence the observed IPD incidence and thereby confound the assessment of vaccine impact [34,77,100]. The same factors can also contribute to settingto-setting variability.…”

Section: Discussionmentioning

confidence: 99%

“…Substantial heterogeneity exists between countries in the quality and methods of their IPD surveillance and in when surveillance was set up relative to PCV introduction [33,34]. For instance, surveillance may cover all cases in a country's population (passive or active national population-based surveillance) or may involve a limited network of hospitals or reporting sites (sentinel surveillance); it may cover all ages or selected age groups; case reporting may be mandatory or voluntary and performed by laboratories and/or clinicians; IPD case definitions and laboratory methods used to confirm cases are not standardized across countries; and serotyping may or may not be done.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution

Izurieta

Bahety²,

Adegbola

et al. 2018

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Pneumococcal conjugate vaccine (PCV) impact studies have reported substantial reductions in the incidence of invasive pneumococcal disease (IPD) after implementation of childhood PCV programs. Heterogeneity in surveillance systems, local epidemiology and PCV programs hampers comparisons between studies. We aimed to better understand the impact of childhood PCV programs on overall IPD and serotype distribution. Areas covered: We analyzed the impact of PCV programs on the incidence of overall IPD, and the distribution of vaccine serotypes (VT) and non-vaccine serotypes (NVT) in children <5 years and adults ≥65 years old. We retrieved datasets from observational post-marketing studies and surveillance reports from countries with high-quality surveillance data available for at least 2 years before PCV program initiation and 3 years after higher-valent PCV implementation. We harmonized pre-and post-PCV analysis periods and assessment methods. Expert commentary: After introduction of pediatric PCV programs, the residual overall IPD burden in children was low and in a narrow range across countries with high vaccination coverage, irrespective of differences in PCV programs and pneumococcal epidemiology. Effects on overall IPD were more variable in the elderly. Whereas IPD was mainly due to VTs before PCV introduction, NVTs are the major contributor today in children and adults.ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution

Izurieta

Bahety²,

Adegbola

et al. 2018

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…The incidence data regarding IPDs vary widely depending on vaccination policy, geographical areas, and differences in the study methodologies and surveillance systems (17,18). In Spain, where PCV7 was introduced in 2001 in the private market, the differences between geographical areas are evident according to the published data.…”

Section: Discussionmentioning

confidence: 99%

Expansion of Serotype Coverage in the Universal Pediatric Vaccination Calendar: Short-Term Effects on Age- and Serotype-Dependent Incidence of Invasive Pneumococcal Clinical Presentations in Madrid, Spain

Picazo¹,

Ruiz–Contreras²,

Casado‐Flores³

et al. 2013

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

“…Therefore, reliable epidemiological data on IPD depend on the quality of surveillance systems and in particular on collaboration between laboratory and clinical facilities. Diverse surveillance systems in many countries of the Region merit improvement (18); in particular, systems of active surveillance are under-represented. In many cases, blood culture is not performed at all, or performed at later stage, or the results are not reported correctly.…”

Section: The Burden Of Ipd -How Much Remains Hidden?mentioning

confidence: 99%

Opportunity for Healthy Ageing: Lessening the Burden of Adult Pneumococcal Disease in Central and Eastern Europe, and Israel

Ludwig¹,

Ünal²,

Bogdan³

et al. 2012

Cent Eur J Public Health

View full text Add to dashboard Cite

SUMMARYThe population of the Region (Central Europe, Eastern Europe, and Israel) is ageing, necessitating preventative programmes to maintain a healthy and active lifestyle in older age groups. Invasive pneumococcal disease (including bacteremic pneumonia, bacteremia without a focus, and meningitis) has higher incidence, morbidity and mortality in older adults and is a substantial public health burden in the ageing population.Surveillance in the Region establishes a significant burden in older adults of invasive pneumococcal disease (IPD), which still appears to be under-estimated as compared with other countries, and this warrants an improvement in surveillance systems. The largest proportion of IPD in adults is bacteremic pneumonia. Community-acquired pneumonia (CAP), largely attributable to S. pneumoniae, can be bacteremic or non-bacteremic; the non-bacteremic forms of CAP also represent a significant burden in the Region.The burden of pneumococcal disease can be reduced with programmes of effective vaccination. Recommendations on pneumococcal vaccination in adults vary widely across the Region. The main barrier to implementation of vaccination programmes is low awareness among healthcare professionals on serious heatlh consequences of adult pneumococcal disease and of vaccination options.The Expert Panel calls on healthcare providers in the Region to improve pneumococcal surveillance, optimize and disseminate recommendations for adult vaccination, and support awareness and education programmes about adult pneumococcal disease. Healthy Ageing: a Growing Public Health IssueThe proportion of adults in the Region (Central Europe, Eastern Europe, and Israel) over the age of 50 years has nearly doubled in the past six decades (Fig. 1) and is forecasted to double again by 2040 (1). As a consequence, the Region will increasingly face the issue of "healthy ageing" (i.e. maintaining the general level of health, quality of life and active lifestyle in an ageing population).

show abstract

Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?

Cited by 26 publications

References 13 publications

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution

Expansion of Serotype Coverage in the Universal Pediatric Vaccination Calendar: Short-Term Effects on Age- and Serotype-Dependent Incidence of Invasive Pneumococcal Clinical Presentations in Madrid, Spain

Opportunity for Healthy Ageing: Lessening the Burden of Adult Pneumococcal Disease in Central and Eastern Europe, and Israel

Contact Info

Product

Resources

About